1. Companies

  2. SK biopharmaceuticals

SK biopharmaceuticals

SK biopharmaceuticals

Developing innovative and next-generation drugs for central nervous system.
Launch date
Employees
201-500 people
Market cap
-
Enterprise valuation
AUD1.1—1.7b (Dealroom.co estimates Nov 2021.)
Seongnam-si Gyeonggi-do (HQ)
http://skbp.com
https://twitter.com/skbiotekhttps://www.linkedin.com/company/sk-biopharmaceuticals
    • Edit
DateInvestorsAmountRound

N/A

Seed
*

$180m

Series A
*

N/A

Grant
Total FundingAUD278m

Recent News about SK biopharmaceuticals

Edit

Investments by SK biopharmaceuticals

Edit
Proteovant Therapeutics
Proteovant Therapeutics
ACQUISITION by SK biopharmaceuticals Jun 2023